Literature DB >> 11834241

Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma.

Akihito Abe1, Yoshimitsu Kiriyama, Masako Hirano, Toshiaki Miura, Hiroyuki Kamiya, Hideyoshi Harashima, Yukiko Tokumitsu.   

Abstract

We examined the effects of troglitazone, one of thiazolidinedione derivatives on human basophilic leukemia cell line KU812. Troglitazone caused the suppression of cell growth, which was suggested to result from the decrease in cyclin E and the hyperphosphorylated form of retinoblastoma tumor suppressor gene product (pRb). In addition, troglitazone caused a decrease in histamine secretion due to the reduced expression of histidine decarboxylase mRNA. Peroxisome proliferator-activated receptor (PPAR)-gamma mRNA was undetectable by reverse transcription-polymerase chain reaction (RT-PCR) in KU812 cells. These findings suggested that troglitazone suppressed cell growth and histamine synthesis independently of PPARgamma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834241     DOI: 10.1016/s0014-2999(01)01577-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

1.  Pomegranate flower improves cardiac lipid metabolism in a diabetic rat model: role of lowering circulating lipids.

Authors:  Tom Hsun-Wei Huang; Gang Peng; Bhavani Prasad Kota; George Qian Li; Johji Yamahara; Basil D Roufogalis; Yuhao Li
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

2.  Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells.

Authors:  Elisabetta Ceni; Tommaso Mello; Mirko Tarocchi; David-W Crabb; Anna Caldini; Pietro Invernizzi; Calogero Surrenti; Stefano Milani; Andrea Galli
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

3.  Activating peroxisome proliferator-activated receptor gamma mutant promotes tumor growth in vivo by enhancing angiogenesis.

Authors:  Lifeng Tian; Jie Zhou; Mathew C Casimiro; Bing Liang; John O Ojeifo; Min Wang; Terry Hyslop; Chenguang Wang; Richard G Pestell
Journal:  Cancer Res       Date:  2009-12-15       Impact factor: 12.701

4.  Peroxisome proliferator-activated receptor gamma ligands inhibit cell growth and induce apoptosis in human liver cancer BEL-7402 cells.

Authors:  Ming-Yi Li; Hua Deng; Jia-Ming Zhao; Dong Dai; Xiao-Yu Tan
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

5.  Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARgamma independent mechanisms.

Authors:  A Galli; E Ceni; D W Crabb; T Mello; R Salzano; C Grappone; S Milani; E Surrenti; C Surrenti; A Casini
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

6.  PPAR gamma signaling exacerbates mammary gland tumor development.

Authors:  Enrique Saez; John Rosenfeld; Antonia Livolsi; Peter Olson; Eleuterio Lombardo; Michael Nelson; Ester Banayo; Robert D Cardiff; Juan Carlos Izpisua-Belmonte; Ronald M Evans
Journal:  Genes Dev       Date:  2004-03-01       Impact factor: 11.361

7.  MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells.

Authors:  J-J Lee; A Drakaki; D Iliopoulos; K Struhl
Journal:  Oncogene       Date:  2011-11-28       Impact factor: 9.867

8.  PPARγ Promotes Growth and Invasion of Thyroid Cancer Cells.

Authors:  William M Wood; Vibha Sharma; Kevin T Bauerle; Laura A Pike; Qiong Zhou; Deborah L Fretwell; Rebecca E Schweppe; Bryan R Haugen
Journal:  PPAR Res       Date:  2011-12-12       Impact factor: 4.964

9.  Down-regulation of PPARgamma1 suppresses cell growth and induces apoptosis in MCF-7 breast cancer cells.

Authors:  Yekaterina Y Zaytseva; Xin Wang; R Chase Southard; Natalie K Wallis; Michael W Kilgore
Journal:  Mol Cancer       Date:  2008-12-05       Impact factor: 27.401

10.  Targeting PPARγ Signaling Cascade for the Prevention and Treatment of Prostate Cancer.

Authors:  Sakshi Sikka; Luxi Chen; Gautam Sethi; Alan Prem Kumar
Journal:  PPAR Res       Date:  2012-11-14       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.